- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Xetra | 89,700 | 11.06.24 15:07:52 | -0,590 | -0,65% | 89,740 | 89,800 | 91,220 | 90,290 |
|
REGENERON PHARMAC.DL-,001 | 881535 | Frankfurt | 926,600 | 11.06.24 08:06:52 | +1,800 | +0,19% | 920,200 | 926,800 | 926,600 | 924,800 |
